The in vivo cell therapy seed Carisma Therapeutics planted with Moderna in 2022 is starting to sprout. | The in vivo cell ...

Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced ...

Presented initial in vivo data for universal liver-targeted LNP and Wilson ... without introducing safety concerns or detectable off-target edits,” said Keith Gottesdiener, M.D., President and Chief ...

Carisma Therapeutics (CARM) announced positive pre-clinical data on its anti-GPC3 in vivo chimeric antigen receptor macrophage and monocyte, or CAR-M, therapy for hepatocellular carcinoma, or HCC, ...

AWARD-WINNING independent Filipino filmmaker Joseph Abello has turned to the vivo V40 to bring his climate advocacy to life in a compelling new short film for Oscar M. Lopez Foundation's 'Mga Kwento ...

Most flagships these days have IP68 dust and water resistance as standard, but with 2025 phones switching to IP69, it's time ...

Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...

Stay updated on Beam Therapeutics Inc.'s latest advancements in Sickle Cell Disease and alpha-1 antitrypsin deficiency treatments. Click for my BEAM stock update.

The vicious attack happened in the lobby of an Arizona Department of Child Safety office. The victim was seriously injured ...

Q3 2024 Earnings Call Transcript November 7, 2024 Intellia Therapeutics, Inc. beats earnings expectations. Reported EPS is $-1.34, expectations were $-1.37. Operator: Good morning and welcome to ...